

DAFTAR PUSTAKA

Aceves, C. *et al.* (2009) "Antineoplastic effect of iodine in mammary cancer: Participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR)," *Molecular Cancer*, 8. Available at: <https://doi.org/10.1186/1476-4598-8-33>.

Albano, D. *et al.* (2018) "Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines," *European Journal of Endocrinology*, 179(3), pp. 143–151. Available at: <https://doi.org/10.1530/EJE-18-0253>.

Albano, D. *et al.* (2019) "Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer," *Endocrine*, 63(1), pp. 79–86. Available at: <https://doi.org/10.1007/s12020-018-1713-2>.

Arroyo-Helguera, O. *et al.* (2006a) "Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line," *Endocrine-Related Cancer*, 13(4), pp. 1147–1158. Available at: <https://doi.org/10.1677/erc.1.01250>.

Arroyo-Helguera, O. *et al.* (2008) "Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects," *Endocrine Related Cancer*, 15(4), pp. 1003–1011. Available at: <https://doi.org/10.1677/ERC-08-0125>.

Arturi, F. *et al.* (2000b) "Sodium±iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas," *European Journal of Endocrinology*, 143, pp. 623–627. Available at: www.eje.org.

Bagchi, N., Shivers, B. and Thomas R. Brown (1985) "Studies on the mechanism of acute inhibition of thyroglobulin hydrolysis by iodine," *European Journal of Endocrinology*, 108(4), pp. 511–517.

Boeynaems, J.M. and Hubbard, W.C. (1980a) "Transformation of arachidonic acid into an Iodolactone by the rat thyroid," *Journal of Biological Chemistry*, 255(19), pp. 9001–9004. Available at: [https://doi.org/10.1016/s0021-9258\(19\)70513-4](https://doi.org/10.1016/s0021-9258(19)70513-4).

Braverman, L. and Utiger, D. (2000b) *Werner and Ingbar's the thyroid: a fundamental and clinical text*. 8th ed. Philadelphia, USA: Lippincott, Williams & Wilkins.

Buffet, C. *et al.* (2020) "Redifferentiation of radioiodine-refractory thyroid cancers," *Endocrine-Related Cancer*. BioScientifica Ltd., pp. R113–R132. Available at: <https://doi.org/10.1530/ERC-19-0491>.

Caballero, Y. *et al.* (2015) "The value of thyroperoxidase as a prognostic factor for differentiated thyroid cancer - A long-term follow-up study," *Thyroid Research*, 8(1), pp. 1–9. Available at: <https://doi.org/10.1186/s13044-015-0022-6>.

Cabral, G.A. (2005) "Lipids as bioeffectors in the immune system," *Life Sciences*, 77(14), pp. 1699–1710. Available at: <https://doi.org/10.1016/j.lfs.2005.05.013>.

Caillou, B. *et al.* (1998) "Na⁺/I⁻ symporter distribution in human thyroid tissues: An immunohistochemical study," *Journal of Clinical Endocrinology and Metabolism*, 83(11), pp. 4102–4106. Available at: <https://doi.org/10.1210/jc.83.11.4102>.

Chiappetta, G. *et al.* (2007) "The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand," *Journal of Clinical Endocrinology and Metabolism*, 92(3), pp. 1159–1163. Available at: <https://doi.org/10.1210/jc.2006-1712>.

Chung, J.-K. (2002) *Sodium Iodide Symporter: Its Role in Nuclear Medicine**, *J Nucl Med*. Available at: http://www.snm.org/education/ce_online.html.

Chung, T. *et al.* (2015) "Glycosylation of sodium/iodide symporter (NIS) regulates its membrane translocation and radioiodine uptake," *PLoS ONE*, 10(11). Available at: <https://doi.org/10.1371/journal.pone.0142984>.

Courtney, A.H., Lo, W.L. and Weiss, A. (2017) "TCR Signaling: Mechanisms of Initiation and Propagation," *Trends in Biochemical Sciences*, 43(2), pp. 108–123. Available at: <https://doi.org/10.1016/j.tibs.2017.11.008>.

D'Agostino, M. *et al.* (2013) "Different expression of TSH receptor and NIS genes in thyroid cancer: Role of epigenetics," *Journal of Molecular Endocrinology*, 52(2), pp. 121–131. Available at: <https://doi.org/10.1530/JME-13-0160>.

Degroot, L.J. and Greer, M.A. (1956) "The effect of stable iodide on thyroid secretion in man," *Metabolism*, 5, pp. 682–696.

Demeester-Mirkin, N. *et al.* (1984) "Iodide Organification Defect in a Cold Thyroid Nodule: Absence of Iodide Effect on Cyclic Amp Accumulation," *Clinical Endocrinology*, 20(4), pp. 473–479. Available at: <https://doi.org/10.1111/j.1365-2265.1984.tb03444.x>.

Díaz Vico, T. *et al.* (2025) "Systemic Therapeutic Options in Radioiodine-Refractory Differentiated Thyroid Cancer: Current Indications and Optimal Timing," *Cancers*. Multidisciplinary Digital Publishing Institute (MDPI). Available at: <https://doi.org/10.3390/cancers17111800>.

Dohán, O. *et al.* (2003a) "The sodium/iodide symporter (NIS): Characterization, regulation, and medical significance," *Endocrine Reviews*, 24(1), pp. 48–77. Available at: <https://doi.org/10.1210/er.2001-0029>.

Dugrillon, A. *et al.* (1990a) "Evidence that an iodolactone mediates the inhibitory effect of iodide on thyroid cell proliferation but not on adenosine 3', 5'-monophosphate formation," *Endocrinology*, 127(1), pp. 337–343. Available at: <https://doi.org/10.1210/endo-127-1-337>.

Dugrillon, A. *et al.* (1994) "Identification of 6-Iodolactone in Iodide Treated Human Goiter and its Inhibitory Effect on Proliferation of Human Thyroid Follicles," *Horm.metabs.Res*, 26, pp. 465–469.

Dugrillon, A. and Gartner, R. (1995a) "δ-Iodolactones decrease epidermal growth factor-induced proliferation and inositol-1,4,5-trisphosphate generation in porcine thyroid follicles - A possible mechanism of growth inhibition by iodide," *European Journal of Endocrinology*, 132(6), pp. 735–743. Available at: <https://doi.org/10.1530/eje.0.1320735>.

Dumont, J.E. *et al.* (1995) "Large goitre as a maladaptation to iodine deficiency," *Clinical Endocrinology*, 43(1), pp. 1–10. Available at: <https://doi.org/10.1111/j.1365-2265.1995.tb01886.x>.

Elliyanti, A. *et al.* (2020a) "Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response," *Nuclear Medicine and Molecular Imaging*, 54(1), pp. 35–42. Available at: <https://doi.org/10.1007/s13139-019-00632-8>.

Elliyanti, A. *et al.* (2021a) "Evaluating the natrium iodide symporter expressions in thyroid tumors," *Open Access Macedonian Journal of Medical Sciences*, 9(B), pp. 18–23. Available at: <https://doi.org/10.3889/oamjms.2021.5534>.

Elliyanti, A. (2022a) "Aspects Considered in Differentiated Thyroid Cancer for Radioiodine Therapy," in Dr.I. Kostoglou-Athanassiou (ed.) *Thyroid Cancer-The Road From Genes to Successful Treatment*. Intech Open.

Elmore, S. (2007) "Apoptosis: A Review of Programmed Cell Death," 4, p. 495516. Elrod, H.A. and Sun, S.Y. (2008) "PPAR γ and apoptosis in cancer," *PPAR Research* [Preprint]. Available at: <https://doi.org/10.1155/2008/704165>.

Elstner, E. *et al.* (1998) "Ligands for peroxisome proliferator-activated receptory and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice," *Proceedings of the National Academy of Sciences of the United States of America*, 95(15), pp. 8806–8811. Available at: <https://doi.org/10.1073/pnas.95.15.8806>.

Faria, M. *et al.* (2021c) "Analysis of nis plasma membrane interactors discloses key regulation by a src/rac1/pak1/pip5k/ezrin pathway with potential implications for radioiodine re-sensitization therapy in thyroid cancer," *Cancers*, 13(21), pp. 1–28. Available at: <https://doi.org/10.3390/cancers13215460>.

Gärtner, R., Rank, P. and Ander, B. (2010) "The role of iodine and δ -iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells," *HORMONES*, 9(1), pp. 60–66.

Ghasemi, M. *et al.* (2021) "The MTT assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis," *International Journal of Molecular Sciences*, 22(23). Available at: <https://doi.org/10.3390/ijms222312827>.

Global Cancer Observatory: Indonesia Fact Sheet 2022 (no date). Available at: <https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf> (Accessed: February 16, 2026).

Halmi, N.S., Stuelke, R.G. and Schnell, M.D. (1956a) "Radioiodide in The Thyroid and in Other," (November).

Hofbauer, L.C. *et al.* (1995) "Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine," *Eur J Endocrinol*, 132(5), pp. 605–610.

Hou, P., Bojdani, E. and Xing, M. (2010a) "Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways," *Journal of Clinical Endocrinology and Metabolism*, 95(2), pp. 820–828. Available at: <https://doi.org/10.1210/jc.2009-1888>.

Indonesia Cancer Statistics 2020 (no date). Available at: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf> (Accessed: February 20, 2026).

Karger, S. *et al.* (2005) *Evaluation of Peroxisome Proliferator-Activated Receptor-Expression in Benign and Malignant Thyroid Pathologies, THYROID*.

Kogai, T. and Brent, G.A. (2012) "The sodium iodide symporter (NIS): Regulation and approaches to targeting for cancer therapeutics," *Pharmacology and Therapeutics*. Elsevier Inc., pp. 355–370. Available at: <https://doi.org/10.1016/j.pharmthera.2012.06.007>.

Kollecker, I. *et al.* (2012) "Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues," *Thyroid*, 22(5), pp. 529–535. Available at: <https://doi.org/10.1089/thy.2011.0311>.

Konaklieva, M. and Plotkin, B. (2012) "Lactones: Generic Inhibitors of Enzymes?," *Mini-Reviews in Medicinal Chemistry*, 5(1), pp. 73–95. Available at: <https://doi.org/10.2174/1389557053402828>.

Krawiec, L. *et al.* (1991a) "Thyroid autoregulation: Evidence for an action of iodoarachidonates and iodide at the cell membrane level," *Hormone and Metabolic Research*, 23(7), pp. 321–325. Available at: <https://doi.org/10.1055/s-2007-1003687>.

Lapillonne, H. *et al.* (2003) "Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells," *Cancer Research*, 63(18), pp. 5926–5939.

Lazar, V., Bidart, J.M., *et al.* (1999) "Expression of the Na⁺/I⁻ symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes," *Journal of Clinical Endocrinology and Metabolism*, 84(9), pp. 3228–3234. Available at: <https://doi.org/10.1210/jc.84.9.3228>.

Li, C.C. *et al.* (2010) "Conserved charged amino acid residues in the extracellular region of sodium/iodide symporter are critical for iodide transport activity," *Journal of Biomedical Science*, 17(1). Available at: <https://doi.org/10.1186/1423-0127-17-89>.

Lin, Y.S. *et al.* (2025) "Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)," *European Journal of Nuclear Medicine and Molecular Imaging*. Springer, pp. 3859–3876. Available at: <https://doi.org/10.1007/s00259-025-07222-1>.

Marques, A.R. *et al.* (2004) "Underexpression of peroxisome proliferator-activated receptor (PPAR) γ in PAX8/PPAR γ -negative thyroid tumours," *British Journal of Cancer*, 91(4), pp. 732–738. Available at: <https://doi.org/10.1038/sj.bjc.6601989>.

Martelli, M.L. *et al.* (2002) "Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth," *Journal of Clinical Endocrinology and Metabolism*, 87(10), pp. 4728–4735. Available at: <https://doi.org/10.1210/jc.2001-012054>.

Martino, E., Bartalena, L. and Pinchera, A. (2000) "Central hypothyroidism," *Werner and Ingbar's the thyroid: a fundamental and clinical text*. 8th ed. Philadelphia, USA: Lippincott, Williams & Wilkins.

Mazzaferri, E. (2000) *Carcinoma of the follicular epithelium*. In: *Clinical text*.

Michalik, L. *et al.* (2006) "International Union of Pharmacology . LXI . Peroxisome Proliferator-Activated Receptors," 58(4), pp. 726–741. Available at: [https://doi.org/10.1124/pr.58.4.5.\(NR1C1\)](https://doi.org/10.1124/pr.58.4.5.(NR1C1)).

Michalik, L., Desvergne, B. and Wahli, W. (2004) "Peroxisome-proliferator-activated receptors and cancers: Complex stories," *Nature Reviews Cancer*, 4(1), pp. 61–70. Available at: <https://doi.org/10.1038/nrc1254>.

Mizukami, Y. and Matsubara, F. (1981) "Correlation between Thyroid Peroxidase Activity and Histopathological and Ultrastructural Changes in Various Thyroid Disease," *Endocrinol. Japon.*, 28(4), pp. 381–389.

Monteagudo E.S *et al.* (1990) "Synthesis and Characterization of Iodinated Derivatives of Arachidonic Acid," *Anal.Asoc.Quim.Argent*, 78 (1), pp. 31–36.

Mu, Z.-Z., Zhang, X. and Lin, Y.-S. (2019a) "Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer," *Chonnam Medical Journal*, 55(3), p. 127. Available at: <https://doi.org/10.4068/cmj.2019.55.3.127>.

Nava-Villalba, M. *et al.* (2015a) "Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone," *Molecular Cancer*, 14(1). Available at: <https://doi.org/10.1186/s12943-015-0436-8>.

Nava-Villalba, M. and Aceves, C. (2014a) "6-Iodolactone, key mediator of antitumoral properties of iodine," *Prostaglandins & Other Lipid Mediators*, 112, pp. 27–33. Available at: <https://doi.org/10.1016/j.prostaglandins.2014.07.001>.

Núñez-Anita, R. E. *et al.* (2009a) "A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer," *Prostaglandins and Other Lipid Mediators*, 89(1–2), pp. 34–42. Available at: <https://doi.org/10.1016/j.prostaglandins.2009.04.001>.

Oh, J.M. and Ahn, B.C. (2021a) "Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS," *Theranostics*, 11(13), pp. 6251–6277. Available at: <https://doi.org/10.7150/thno.57689>.

Ohayon, R. *et al.* (1994) "Inhibition of thyroid NADPH-oxidase by 2-iodohexadecanal in a cell-free system," *Molecular and Cellular Endocrinology*, 99(1), pp. 133–141. Available at: [https://doi.org/10.1016/0303-7207\(94\)90156-2](https://doi.org/10.1016/0303-7207(94)90156-2).

Ohta, K. *et al.* (2001) *Ligands for Peroxisome Proliferator-Activated Receptor Inhibit Growth and Induce Apoptosis of Human Papillary Thyroid Carcinoma Cells*, *J Clin Endocrinol Metab*.

Panneels, V. *et al.* (1996) "Biosynthesis and metabolism of 2-iodohexadecanal in cultured dog thyroid cells," *Journal of Biological Chemistry*, 271(38), pp. 23006–23014. Available at: <https://doi.org/10.1074/jbc.271.38.23006>.

Panneels, V. *et al.* (2009a) *Iodide Effects on the Thyroid: Biochemical, Physiological, Pharmacological, and Clinical Effects of Iodide in the Thyroid, Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects*. Elsevier Inc. Available at: <https://doi.org/10.1016/B978-0-12-374135-6.00032-7>.

Park, J.-W. *et al.* (2005) *Troglitazone, the Peroxisome Proliferator-Activated Receptor-Agonist, Induces Antiproliferation and Redifferentiation in Human Thyroid Cancer Cell Lines*, *THYROID*.

Pascual, G. *et al.* (2005) *A sumoylation-dependent pathway mediating transrepression of inflammatory response genes by PPAR γ* NIH Public Access, *Nature*.

Pereira, A. *et al.* (1990) "Identification of a major iodolipid from the horse thyroid gland as 2-iodohexadecanal," *Journal of Biological Chemistry*, 265(28), pp. 17018–17025. Available at: [https://doi.org/10.1016/s0021-9258\(17\)44862-9](https://doi.org/10.1016/s0021-9258(17)44862-9).

Pisarev, M.A. *et al.* (1970) "Serum TSH and thyroxine in goitrous subjects in Argentina," *Journal of Clinical Endocrinology and Metabolism*, 30(5), pp. 680–681. Available at: <https://doi.org/10.1210/jcem-30-5-680>.

Pisarev, M.A. *et al.* (1992a) "Effect of iodoarachidonates on thyroid FRTL-5 cells growth," *Hormone and Metabolic Research*, 24(12), pp. 558–561. Available at: <https://doi.org/10.1055/s-2007-1003389>.

Reka, A.K. *et al.* (2010a) "Peroxisome Proliferator Activated Receptor- γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3 Mediated Epithelial Mesenchymal Transition," *Mol Cancer Ther*, 9(12), pp. 3221–3232.

Ribble, D. *et al.* (2005) "A simple technique for quantifying apoptosis in 96-well plates," *BMC Biotechnology*, 5. Available at: <https://doi.org/10.1186/1472-6750-5-12>.

R.Langer *et al.* (2003) "Influence of Iodide and Iodolactones on Thyroid Apoptosis," *Exp Clin Endocrinol Diabetes*, 111, pp. 325–329.

Romei, C. *et al.* (2008) "BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer," *Endocrine-Related Cancer*, 15(2), pp. 511–520. Available at: <https://doi.org/10.1677/ERC-07-0130>.

Rösner, H. *et al.* (2010) "Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis," *Experimental and Clinical Endocrinology and Diabetes*, 118(7), pp. 410–419. Available at: <https://doi.org/10.1055/s-0029-1225615>.

Russo, Diego *et al.* (2001) *Absence of Sodium/Iodide Symporter Gene Mutations in Differentiated Human Thyroid Carcinomas*, *THYROID*. Mary Ann Liebert, Inc.

Russo, D. *et al.* (2001) "Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas," *Thyroid*, 11(1), pp. 37–39. Available at: <https://doi.org/10.1089/10507250150500649>.

van Sande, J. *et al.* (1975b) "Inhibition by iodide of the activation of the thyroid cyclic 3',5'-AMP system," *Endocrinology*, 96(3), pp. 781–786. Available at: <https://doi.org/10.1210/endo-96-3-781>.

Van Sande, J. and Dumont, J.E. (1973) "Effects of thyrotropin, prostaglandin E1 and iodide on cyclic 3',5'-AMP concentration in dog thyroid slices," *BBA - General Subjects*, 313(2), pp. 320–328. Available at: [https://doi.org/10.1016/0304-4165\(73\)90031-7](https://doi.org/10.1016/0304-4165(73)90031-7).

Schlumberger, M. *et al.* (1980) "Circulating Thyroglobulin and Thyroid Hormones in Patients with Metastases of Differentiated Thyroid Carcinoma : Relationship to Serum Thyrotropin Levels," 51(3).

Schlumberger, M. *et al.* (1983) "Relationship between Thyrotropin Stimulation and Radioiodine Uptake in Lung Metastases of Differentiated Thyroid Carcinoma," 57(1), pp. 148–151.

Schlumberger, M. *et al.* (1996) "Radioactive Iodine Treatment and External Radiotherapy for Lung and Bone Metastases from Thyroid Carcinoma with," 37(4).

Senga, S. *et al.* (2018) "A novel fatty acid-binding protein 5-estrogen-related receptor α signaling pathway promotes cell growth and energy metabolism in prostate cancer cells," *Oncotarget*, 9(60), pp. 31753–31770. Available at: <https://doi.org/10.18632/oncotarget.25878>.

Sertznig, P. *et al.* (2007) "Present concepts and future outlook: Function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer," *Journal of Cellular Physiology*, pp. 1–12. Available at: <https://doi.org/10.1002/jcp.20998>.

Sladek, F.M. (2011) "What are Nuclear Receptor Ligands?," *Mol Cell Endocrinol*, 334(1–2), pp. 3–13. Available at: <https://doi.org/10.1038/nature08365.Reconstructing>.

Sodré, A.K.M.B. *et al.* (2008) "Association of Low Sodium-Iodide Symporter Messenger Ribonucleic Acid Expression in Malignant Thyroid Nodules with Increased Intracellular Protein Staining," *The Journal of Clinical Endocrinology & Metabolism*, 93(10), pp. 4141–4145. Available at: <https://doi.org/10.1210/jc.2007-0353>.

Tachibana, K. *et al.* (2005) "Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing PPAR isoforms," *Nuclear Receptor*, 3, pp. 1–17. Available at: <https://doi.org/10.1186/1478-1336-3-3>.

Tavares, C. *et al.* (2018) "NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features," *Endocrine Connections*, 7(1), pp. 78–90. Available at: <https://doi.org/10.1530/EC-17-0302>.

The World Cell Factory (no date) *Human Thyroid Cancer Cells, B-CPAP Catalog Number: iCell-h022*. Available at: www.icellbioscience.net.

Tonacchera, M. *et al.* (2002) "Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein," *Journal of Clinical Endocrinology and Metabolism*, 87(1), pp. 352–357. Available at: <https://doi.org/10.1210/jcem.87.1.8173>.

Tontonoz, P. and Spiegelman, B.M. (2008) "Fat and beyond: The diverse biology of PPAR γ ," *Annual Review of Biochemistry*, pp. 289–312. Available at: <https://doi.org/10.1146/annurev.biochem.77.061307.091829>.

Vitale, M. *et al.* (2000) "Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress," *Endocrinology*, 141(2), pp. 598–605. Available at: <https://doi.org/10.1210/endo.141.2.7291>.

Wolff, J. (1969a) "Iodide goiter and the pharmacologic effects of excess iodide," *The American Journal of Medicine*, 47(1), pp. 101–124. Available at: [https://doi.org/10.1016/0002-9343\(69\)90245-9](https://doi.org/10.1016/0002-9343(69)90245-9).

Wolff, J. and Chaikoff, I.L. (1948a) "Plasma inorganic iodide, a chemical regulator of normal thyroid function," *Endocrinology*, 42(6), pp. 468–471. Available at: <https://doi.org/10.1210/endo-42-6-468>.

World Health Organization (2022) *Global Cancer Observatory*.

Xu, R.-Q. *et al.* (2023) "Sophorolipid inhibits histamine-induced itch by decreasing PLC/IP3R signaling pathway activation and modulating TRPV1 activity," *Scientific Reports*, 13(1), p. 7957. Available at: <https://doi.org/10.1038/s41598-023-35158-9>.

Yang, S. *et al.* (2021) "Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer," *Frontiers in Endocrinology*, 12. Available at: <https://doi.org/10.3389/fendo.2021.708248>.

Yin, F. *et al.* (2001) "Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators," *Biochemical and Biophysical Research Communications*, 286(5), pp. 916–922. Available at: <https://doi.org/10.1006/bbrc.2001.5491>.

Zhang, H. and Chen, D. (2018) "Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells," *Thyroid Research*, 11(1). Available at: <https://doi.org/10.1186/s13044-018-0057-6>.

Zou, W. *et al.* (2007) “PPAR γ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells,” *Cancer Biology and Therapy*, 6(1), pp. 99–106. Available at: <https://doi.org/10.4161/cbt.6.1.3555>.

